Emory University

The Florida State University Research Foundation, Inc

The Scripps Research Institute

Erwin Van Meir

Kyriacos Costa Nicolaou

Binghe Wang

Mark M Goodman

Xingyue Ji

Anthony Roecker

Ainsley C Nicholson

Dawn E Post

Jalisa Holmes Ferguson

Jiyoung Mun

Stefan Kaluz

Chalet Tan

This disclosure relates to benzhydrol derivatives for managing conditions related to the Hypoxia Inducible Factor (HIF) pathway such as uses in treating cancer. In certain embodiment, the disclosure contemplates compounds and pharmaceutical compositions. In certain embodiment, the disclosure contemplates compounds disclosed herein as prodrugs, optionally substituted with one or more substituents, derivatives, or salts thereof.

Benzhydrol derivatives for the management of conditions related to hypoxia inducible factors

This disclosure relates to Hypoxia Inducible Factor-1 pathway inhibitors and uses as anticancer and imaging agents. In certain embodiments, the disclosure contemplates compounds and pharmaceutical compositions disclosed herein.

Hypoxia inducible factor-1 pathway inhibitors and uses as anticancer and imaging agents

Inhibitors of the Hypoxia Inducible Factor (HIF) and angiogenesis and their methods of use including the treatment of cancer, hypoxia related pathologies, disorders leading to ischemia, for example stroke and ischemic heart disease, and non-cancerous angiogenic diseases are provided.

Inhibitors of HIF and angiogenesis

HIF-1 inhibitors and methods of use thereof are provided.

HIF inhibitors

HIF-1 inhibitors and methods of their use are provided. In particular, 2,2-dimethylbenzopyran based compounds and methods of their use, for example in the treatment or prevention of hypoxia-related pathologies are provided.

HIF-1 inhibitors

The present invention relates to compositions comprising a novel recombinant virus which replicates selectively in cells or tissues that are hypoxic or have an activated HIF pathway. The novel compositions of the invention comprise a recombinant virus genetically engineered to have a hypoxia/HIF-responsive element, or a multiplicity of such elements, operably linked to a promoter which is in turn operably linked to a nucleic acid(s) encoding a peptide(s) which regulates or modulates replication of the virus and/or encode a therapeutic molecule. The invention also includes constructs useful for screening of agents which interact with proteins or genes in the hypoxia-inducible pathway or are jointly translated under hypoxia and animal models useful for monitoring a variety of hypoxic conditions in a non-invasive manner.

Growing community of inventors

Tucker, GA, United States of America

Erwin Van Meir